ResApp Receives $1.8 Million R&D Tax Incentive Cash Rebate

Brisbane, Australia, 12 December 2019 – ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, today announced that it has received $1,798,086 from its Research and Development (R&D) tax incentive claim for the financial year ending 30 June 2019. The Australian Federal Government's R&D Tax Incentive program provides a cash refund on eligible research and development activities performed by Australian companies.

Tony Keating, CEO and Managing Director of ResApp commented, "We are again grateful for the Federal Government's continued support of R&D by Australian companies. Over the past four years, the program has helped us invest in the continued development of our audio-based machine learning algorithms, resulting in the world's first clinical-validated and regulatory-approved smartphone application for acute respiratory diagnosis. This year's rebate further strengthens our balance sheet and allows us to continue to invest resources and accelerate commercialisation."

###

About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease. ResApp's machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional hardware. Clinical studies at leading hospitals in Australia and the United States have demonstrated accurate diagnosis of lower respiratory tract disease, upper respiratory tract infections, asthma/reactive airway disease, pneumonia, bronchiolitis, croup, chronic obstructive pulmonary disease and obstructive sleep apnoea. ResApp's smartphone-based acute respiratory disease diagnostic test, ResAppDx-EU, is CE Marked in the European Union and TGA approved in Australia. Potential customers of ResApp's products include healthcare providers in telehealth, emergency department, urgent care and primary care settings as well as humanitarian organisations in the developing world. For more information, please visit www.resapphealth.com.au.

Contacts

Dr Tony Keating
CEO and Managing Director
+61 430 180 659
tony@resapphealth.com.au

Mr Brian Leedman
Vice President, Corporate Affairs
+61 412 281 780
brian@resapphealth.com.au

This ASX announcement was approved and authorised for release by the board of directors of ResApp Health.